JP2018537453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537453A5 JP2018537453A5 JP2018524831A JP2018524831A JP2018537453A5 JP 2018537453 A5 JP2018537453 A5 JP 2018537453A5 JP 2018524831 A JP2018524831 A JP 2018524831A JP 2018524831 A JP2018524831 A JP 2018524831A JP 2018537453 A5 JP2018537453 A5 JP 2018537453A5
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- powder formulation
- mixing
- production method
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 238000009472 formulation Methods 0.000 claims 13
- 238000004519 manufacturing process Methods 0.000 claims 11
- 239000000843 powder Substances 0.000 claims 10
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 claims 5
- 239000011362 coarse particle Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 4
- 239000003149 muscarinic antagonist Substances 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229940112141 dry powder inhaler Drugs 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000010419 fine particle Substances 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims 2
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 238000009826 distribution Methods 0.000 claims 2
- -1 fatty acid salt Chemical class 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims 2
- 229940125389 long-acting beta agonist Drugs 0.000 claims 2
- NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 claims 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 claims 1
- WOVFJBGKJQEQQD-UHFFFAOYSA-N acridine;hydrobromide Chemical compound [Br-].C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 WOVFJBGKJQEQQD-UHFFFAOYSA-N 0.000 claims 1
- 230000001022 anti-muscarinic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 229960004078 indacaterol Drugs 0.000 claims 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims 1
- 229960002744 mometasone furoate Drugs 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- YZNWXXJZEDHRKB-UHFFFAOYSA-N octadecyl 2-hydroxypropanoate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOC(=O)C(C)O YZNWXXJZEDHRKB-UHFFFAOYSA-N 0.000 claims 1
- 229960004286 olodaterol Drugs 0.000 claims 1
- COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 229960000257 tiotropium bromide Drugs 0.000 claims 1
- 229960004541 umeclidinium bromide Drugs 0.000 claims 1
- PEJHHXHHNGORMP-AVADPIKZSA-M umeclidinium bromide Chemical compound [Br-].C=1C=CC=CC=1C([C@@]12CC[N@@+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 PEJHHXHHNGORMP-AVADPIKZSA-M 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194661.3 | 2015-11-16 | ||
| EP15194661 | 2015-11-16 | ||
| PCT/EP2016/077566 WO2017085007A1 (en) | 2015-11-16 | 2016-11-14 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537453A JP2018537453A (ja) | 2018-12-20 |
| JP2018537453A5 true JP2018537453A5 (enExample) | 2019-12-12 |
| JP6942126B2 JP6942126B2 (ja) | 2021-09-29 |
Family
ID=54548063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524831A Active JP6942126B2 (ja) | 2015-11-16 | 2016-11-14 | 抗コリン作用薬、コルチコステロイド及びβ−アドレナリン作用薬を含む乾燥粉末製剤の製造方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10086003B2 (enExample) |
| EP (2) | EP3689379B1 (enExample) |
| JP (1) | JP6942126B2 (enExample) |
| KR (1) | KR20180082442A (enExample) |
| CN (1) | CN108348614B (enExample) |
| AR (1) | AR106687A1 (enExample) |
| AU (1) | AU2016357988B2 (enExample) |
| CA (1) | CA3005291C (enExample) |
| CL (1) | CL2018001297A1 (enExample) |
| CO (1) | CO2018005139A2 (enExample) |
| DK (2) | DK3377109T3 (enExample) |
| EA (1) | EA037346B1 (enExample) |
| ES (2) | ES2890409T3 (enExample) |
| GE (2) | GEP20207178B (enExample) |
| HR (2) | HRP20211599T1 (enExample) |
| HU (2) | HUE056402T2 (enExample) |
| IL (1) | IL259327B (enExample) |
| MA (1) | MA52437A (enExample) |
| MX (1) | MX377113B (enExample) |
| MY (1) | MY198321A (enExample) |
| PE (1) | PE20181377A1 (enExample) |
| PH (1) | PH12018501023B1 (enExample) |
| PL (2) | PL3377109T3 (enExample) |
| PT (2) | PT3689379T (enExample) |
| SA (1) | SA518391574B1 (enExample) |
| SG (2) | SG11201804048WA (enExample) |
| SI (2) | SI3689379T1 (enExample) |
| TW (1) | TWI729025B (enExample) |
| UA (1) | UA125173C2 (enExample) |
| WO (1) | WO2017085007A1 (enExample) |
| ZA (1) | ZA201803167B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3621590B1 (en) | 2017-05-11 | 2021-09-01 | Chiesi Farmaceutici S.p.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| MA48620A (fr) * | 2017-05-11 | 2021-04-28 | Chiesi Farm Spa | Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique |
| WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| CN112823009A (zh) * | 2019-08-28 | 2021-05-18 | 上海谷森医药有限公司 | 糠酸氟替卡松脂质体制剂及其制备方法 |
| WO2021143785A1 (zh) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
| CN111467498A (zh) * | 2020-05-14 | 2020-07-31 | 王兆霖 | 药物组合物制剂 |
| CN117064869A (zh) * | 2023-09-27 | 2023-11-17 | 山东京卫制药有限公司 | 一种胶囊型吸入粉雾剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| PT1386630E (pt) | 2002-07-31 | 2006-09-29 | Chiesi Farma Spa | Inalador em po |
| JP2009514779A (ja) * | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
| GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| DK2560611T3 (en) | 2010-04-21 | 2018-02-26 | Chiesi Farm Spa | Process for providing particles with reduced electrostatic charges |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| KR102275904B1 (ko) * | 2013-07-11 | 2021-07-13 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제 |
-
2016
- 2016-11-14 PT PT201568151T patent/PT3689379T/pt unknown
- 2016-11-14 GE GEAP201614782A patent/GEP20207178B/en unknown
- 2016-11-14 DK DK16801984.2T patent/DK3377109T3/da active
- 2016-11-14 JP JP2018524831A patent/JP6942126B2/ja active Active
- 2016-11-14 KR KR1020187013284A patent/KR20180082442A/ko not_active Withdrawn
- 2016-11-14 PL PL16801984T patent/PL3377109T3/pl unknown
- 2016-11-14 PE PE2018000972A patent/PE20181377A1/es unknown
- 2016-11-14 SG SG11201804048WA patent/SG11201804048WA/en unknown
- 2016-11-14 MX MX2018005979A patent/MX377113B/es active IP Right Grant
- 2016-11-14 MY MYPI2018000703A patent/MY198321A/en unknown
- 2016-11-14 SI SI201631330T patent/SI3689379T1/sl unknown
- 2016-11-14 CA CA3005291A patent/CA3005291C/en active Active
- 2016-11-14 PT PT168019842T patent/PT3377109T/pt unknown
- 2016-11-14 SG SG10201912090UA patent/SG10201912090UA/en unknown
- 2016-11-14 AR ARP160103472A patent/AR106687A1/es not_active Application Discontinuation
- 2016-11-14 ES ES20156815T patent/ES2890409T3/es active Active
- 2016-11-14 MA MA052437A patent/MA52437A/fr unknown
- 2016-11-14 GE GEAP202014782A patent/GEAP202014782A/en unknown
- 2016-11-14 HR HRP20211599TT patent/HRP20211599T1/hr unknown
- 2016-11-14 EA EA201890967A patent/EA037346B1/ru unknown
- 2016-11-14 EP EP20156815.1A patent/EP3689379B1/en active Active
- 2016-11-14 AU AU2016357988A patent/AU2016357988B2/en active Active
- 2016-11-14 SI SI201630738T patent/SI3377109T1/sl unknown
- 2016-11-14 HR HRP20200571TT patent/HRP20200571T1/hr unknown
- 2016-11-14 WO PCT/EP2016/077566 patent/WO2017085007A1/en not_active Ceased
- 2016-11-14 DK DK20156815.1T patent/DK3689379T3/da active
- 2016-11-14 ES ES16801984T patent/ES2789365T3/es active Active
- 2016-11-14 HU HUE20156815A patent/HUE056402T2/hu unknown
- 2016-11-14 HU HUE16801984A patent/HUE050343T2/hu unknown
- 2016-11-14 CN CN201680066805.3A patent/CN108348614B/zh active Active
- 2016-11-14 PL PL20156815T patent/PL3689379T3/pl unknown
- 2016-11-14 EP EP16801984.2A patent/EP3377109B1/en active Active
- 2016-11-14 TW TW105137047A patent/TWI729025B/zh active
- 2016-11-14 UA UAA201805272A patent/UA125173C2/uk unknown
- 2016-11-15 US US15/351,510 patent/US10086003B2/en active Active
-
2018
- 2018-05-14 ZA ZA2018/03167A patent/ZA201803167B/en unknown
- 2018-05-14 IL IL259327A patent/IL259327B/en active IP Right Grant
- 2018-05-14 SA SA518391574A patent/SA518391574B1/ar unknown
- 2018-05-14 CL CL2018001297A patent/CL2018001297A1/es unknown
- 2018-05-15 PH PH12018501023A patent/PH12018501023B1/en unknown
- 2018-05-16 CO CONC2018/0005139A patent/CO2018005139A2/es unknown
- 2018-08-27 US US16/113,051 patent/US10786451B2/en active Active
-
2020
- 2020-08-06 US US16/986,796 patent/US10959944B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537453A5 (enExample) | ||
| JP2019501876A5 (enExample) | ||
| JP5809985B2 (ja) | ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤 | |
| HRP20200537T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| RU2012145762A (ru) | Способ получения частиц с пониженным электростатическим зарядом | |
| JP2013542940A5 (enExample) | ||
| JP2015519356A5 (enExample) | ||
| JP2009541393A (ja) | グリコピロニウム塩の吸入用組成物 | |
| HRP20200571T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| PT1545634E (pt) | Método para preparar composições de pó seco para inalação | |
| JP2020023537A (ja) | Ｃｏｐｄの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ | |
| CN104955448A (zh) | 适用于吸入治疗的包含多组分结晶颗粒的药物组合物 | |
| CA2838031A1 (en) | Dry powder inhaler compositions comprising umeclidinium | |
| EP2682099B1 (en) | Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists | |
| AU2013275641B2 (en) | Method for producing powder for inhalation | |
| EP2821062A1 (en) | Novel dry powder inhaler formulations | |
| JP5345605B2 (ja) | 乾燥粉末吸入組成物の製造方法 | |
| CN107213141A (zh) | 用于吸入的药物组合物 | |
| NZ742473B2 (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| WO2019060595A1 (en) | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM | |
| NZ742474B2 (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |